The novel development of a key drug for epilepsy by a prominent pharmaceutical company has been met with optimism. The drug, known as Brivanext, has been developed with an Active Pharmaceutical Ingredient (API) and comes as a fully formulated single-dose solution. This article will discuss the implications of this breakthrough, the nature of epilepsy, and the role of APIs in the pharmaceutical industry.
Epilepsy: Understanding the Disorder
Epilepsy is classified as a central nervous system or neurological disorder. It results from abnormal brain activity, translating into seizures or unusual behaviour, sensations, and periods when a person may lose awareness. It stands as the fourth most prevalent neurological disorder globally and doesn’t discriminate based on age. Both the young and elderly can develop epilepsy. Interestingly, it slightly affects more males than females.
Symptoms of Epilepsy
Epileptic patients exhibit symptoms that may alter sense perceptions such as taste, smell, sight, hearing, and touch. Other notable signs include dizziness, tingling and twitching of limbs, unresponsive spells, and repetitive movements. One might experience periods of staring blankly or lose consciousness, although not everyone suffer this effect.
Management and Treatment of Epilepsy
While there’s no known cure for epilepsy, it can be controlled. The cornerstone of managing epilepsy involves medications and adopting specific strategies to mitigate episodes. These measures aim at reducing the frequency of seizures and improving the quality of life for patients.
Initiatives to Promote Awareness about Epilepsy
In 2019, the World Health Organization released a report titled “Epilepsy, a Public Health Imperative”. The publication marked the first global examination on epilepsy, incorporating evidence on the burden of the disorder. It also offered suggestions for public health responses needed at the global, regional, and national levels.
Active Pharmaceutical Ingredients (APIs) and Their Significance
APIs or bulk drugs stand as essential components in drug manufacturing. The Hubei province in China serves as the nerve center of the API production industry. India, among other countries, heavily relies on China for API imports, spending about $3.5 billion annually on these substances. Around 70% or $2.5 billion of this amount is sourced from China.
Evidently, the development of Brivanext marks a significant milestone in neurology. The drug provides hope for improved quality of life for epilepsy patients, emphasizing the importance of continued research in this field.
Last Modified: February 10, 2024